Hillevax, INC 8-K filings

HilleVax, Inc. has completed its acquisition by XOMA Royalty Corporation for $1.95 cash plus a contingent value right per share, leading to its delisting from Nasdaq.

HilleVax, Inc. reported its second quarter 2025 financial results, alongside the announcement of a definitive merger agreement to be acquired by XOMA Royalty Corporation for $1.95 per share plus a contingent value right.

HilleVax, a clinical-stage biopharmaceutical company, has entered into a definitive merger agreement to be acquired by XOMA Royalty Corporation for $1.95 per share in cash plus a contingent value right.

HilleVax, Inc. announced the successful election of three Class III directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm for fiscal year 2025 at its Annual Meeting of Stockholders held on June 23, 2025.

HilleVax reported its Q1 2025 financial results, showing a reduced net loss and lower operating expenses, while also exploring strategic alternatives for its norovirus vaccine candidates.

HilleVax reports its full year 2024 financial results, highlighting $171.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024, and exploring strategic alternatives for its norovirus vaccine candidates.

HilleVax, Inc. is reducing its workforce by 70% and seeing the departure of key executives as it explores strategic alternatives for its norovirus vaccine candidates.

HilleVax announced its third quarter 2024 financial results, highlighting a decrease in operating expenses and a net loss of $25.8 million, while also exploring strategic options for its norovirus vaccine candidates.

HilleVax, Inc. has announced a workforce reduction of approximately 25% as it explores strategic alternatives for its norovirus vaccine candidates.

HilleVax reported its Q2 2024 financial results, highlighted by a significant workforce reduction and a strategic shift following disappointing clinical trial results for its HIL-214 vaccine candidate.

HilleVax, Inc. is reducing its workforce by approximately 40% to cut operating expenses while it explores options for its norovirus vaccine candidates.

HilleVax, Inc. fully repaid its $26.2 million loan with Hercules Capital, including fees, totaling $28.5 million, and terminated the loan agreement.

HilleVax announced that its Phase 2b clinical trial for HIL-214 in infants did not meet its primary endpoint, leading to the discontinuation of its development for this age group.

HilleVax, Inc. amended its charter to limit officer liability and elected three Class II directors at its 2024 Annual Meeting of Stockholders.

HilleVax announced its first quarter 2024 financial results, highlighting progress on its norovirus vaccine candidate, HIL-214, and anticipating topline data from its Phase 2B clinical trial in mid-2024.

HilleVax announced its full year 2023 financial results, highlighting progress in its HIL-214 norovirus vaccine program and upcoming milestones.

HilleVax, Inc. has appointed Sean McLoughlin as its new Chief Operating Officer, effective January 16, 2024, while also announcing other executive transitions.